Related Experiment Videos
Impact of an intermittent catheterization program on children with myelomeningocele
Insights
Intermittent catheterization programs (ICP) help children with myelomeningocele achieve dryness and reduce infections. Long-term ICP use shows significant benefits, aiding decisions on newborn treatment.
Area of Science:
- Pediatric Urology
- Nephrology
- Developmental Pediatrics
Background:
- Myelomeningocele is a complex congenital condition affecting bladder and bowel function.
- Management of bladder dysfunction in myelomeningocele is crucial for preventing complications.
Purpose of the Study:
- To evaluate the long-term outcomes of intermittent catheterization programs (ICP) in children with myelomeningocele.
- To assess the impact of ICP on continence, urinary tract infections (UTIs), and renal status.
Main Methods:
- Retrospective analysis of 164 children with myelomeningocele followed in a specialized clinic.
- Evaluation of outcomes in 53 children on ICP for 5 years or more.
Main Results:
- 52% of children were on an intermittent catheterization program (ICP).
- A high percentage of children on ICP for over 5 years achieved satisfactory dryness.
- Long-term ICP use was associated with decreased UTI frequency and improved renal status.
Conclusions:
- Intermittent catheterization programs (ICP) offer significant long-term benefits for children with myelomeningocele.
- ICP can improve quality of life by enhancing continence and reducing infections.
- The positive outcomes of ICP should be considered in treatment decisions for newborns with myelomeningocele.
Abstract:
Among 164 children being followed in a myelomeningocele clinic, 85 (52%) are on an intermittent catheterization program (ICP). Among 53 children on ICP for 5 years or more, a high percentage have achieved satisfactory dryness, decreased frequency of urinary tract infection, and improvement in renal status. The potential for improved well-being afforded by ICP is one factor that should be considered in decisions about "active" or "supportive" treatment in newborn infants with myelomeningocele.